Jane Sayi - Concepedia

Author

Jane Sayi

Muhimbili University of Health and Allied Sciences

Also Known As

J G Sayi, J Sayi, J. G. Sayi, J. Sayi, J.G Sayi, J.G. Sayi, Jane G. Sayi, Jane Sayi

Publications

Citations

H-Index

Concepts

All Affiliations

Muhimbili University of Health and Allied Sciences Karolinska Institutet Karolinska University Hospital University of Zimbabwe University of Bahrain

About

Jane Sayi is an author at Muhimbili University of Health and Allied Sciences specializing in medicine, genetics, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	354
2	Public Health	2	2	89
3	Epidemiology	2	2	89
4	Natural Sciences	1	1	47
5	Biochemistry	1	1	47

Jane Sayi

Publications

919

Citations

H-Index

Page 1

	Year	Citations
4β-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians Ulf Diczfalusy, Jun Miura, Hyung‐Keun Roh, Pharmacogenetics and Genomics	2008	145
Phenotype–genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles Cristina Rodríguez‐Antona, Jane Sayi, Lars L. Gustafsson, Biochemical and Biophysical Research Communications Allelic VariantMedicineGeneticsPharmacologyHuman Polymorphism	2005	111
Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients Collet Dandara, Collen Masimirembwa, Ayoub Magimba, European Journal of Clinical Pharmacology PsychiatryPsychiatric DisordersGeneticsPsychiatric GeneticsPsychiatric Patients	2001	101
The African‐specific <i>CYP2D6*17</i> allele encodes an enzyme with changed substrate specificity Agneta Wennerholm, Collet Dandara, Jane Sayi, Clinical Pharmacology & Therapeutics	2001	91
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population Rajaa A. Mirghani, Jane Sayi, Eleni Aklillu, Pharmacogenetics and Genomics	2006	86
CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir Filip Josephson, Annika Allqvist, Mohamed Janabi, Clinical Pharmacology & Therapeutics	2007	63
Genetic Polymorphism of Cytochrome P450 1A1 (CYP1A1) and Glutathione Transferases (M1, T1 and P1) among Africans Collet Dandara, Jane Sayi, Collen Masimirembwa, Clinical Chemistry and Laboratory Medicine (CCLM) Glutathione TransferasesGenotype-phenotype AssociationVariant InterpretationMedicineGenetics	2002	59
Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations Eleni Aklillu, Roberto Canaparo, Mia Sandberg, European Journal of Clinical Pharmacology Human VariationGenetic EpidemiologyHuman PolymorphismBlack-african PopulationsPublic Health	2002	53
Arylamine N-acetyltransferase (NAT2) genotypes in Africans Collet Dandara, Collen Masimirembwa, Ayoub Magimba, Pharmacogenetics	2003	48
Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans Tashinga E. Bapiro, Jane Sayi, Julia A. Hasler, European Journal of Clinical Pharmacology Medicinal ChemistryBiochemistryMedicineNatural SciencesHerb-drug Interaction	2005	47

Page 1